Eisai (ESAIY) and Biogen (BIIB) announced that Health Canada has issued a Notice of Compliance with Conditions for humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease who are apolipoprotein E 4 non-carriers or heterozygotes and who have confirmed amyloid pathology. LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Strategic Acquisition of Vanqua Bio’s Asset Bolsters Immunology Portfolio, Justifying Buy Rating
- Biogen licenses oral C5aR1 antagonist from Vanqua Bio
- Biogen to present additional results from Phase 3 study of dapirolizumab pegol
- Biogen’s Hold Rating Justified by Limited Growth Prospects and Pipeline Uncertainty
- Biogen price target raised to $153 from $135 at Citi